Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355849 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT00355849 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 555 participants.
The verdict
NCT00355849, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder \[also known as AIR® Inhaled Insulin\]\[AIR® is a registered trademark of Alkermes,Inc.\] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is intended to determine if mealtime AIR® Insulin may be superior to once-daily insulin glargine injections.
Interventions
- DRUG Insulin Glargine
- DRUG Human Insulin Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355849
The ClinicalTrials.gov registry entry for NCT00355849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 555 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00355849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355849 about?
NCT00355849 is a clinical study titled "Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes". A study to evaluate the efficacy and safety of Human Insulin Inhalation Powder \[also known as AIR® Inhaled Insulin\]\[AIR® is a registered trademark of Alkermes,Inc.\] in patients with Type 2 diabetes who are currently being treated with once daily insulin glargine injections. The present study is ...
What is the current status of trial NCT00355849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2006-08. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00355849?
The interventions under investigation include: Insulin Glargine (DRUG), Human Insulin Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT00355849?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.